These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39013121)

  • 1. Development of a Web-Based Interactive Tool for Visualizing Breast Cancer Clinical Trial Tolerability Data.
    Luu M; Gresham G; Henry L; Kim S; Rogatko A; Yothers G; Hays RD; Tighiouart M; Ganz PA
    JCO Clin Cancer Inform; 2024 Jul; 8():e2400007. PubMed ID: 39013121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35.
    Henry NL; Kim S; Hays RD; Diniz MA; Luu M; Cecchini RS; Yothers G; Rogatko A; Ganz PA
    J Clin Oncol; 2021 Dec; 39(34):3800-3812. PubMed ID: 34554865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualizing adverse events in clinical trials using correspondence analysis with R-package visae.
    Diniz MA; Gresham G; Kim S; Luu M; Henry NL; Tighiouart M; Yothers G; Ganz PA; Rogatko A
    BMC Med Res Methodol; 2021 Nov; 21(1):244. PubMed ID: 34753452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial.
    Calsavara VF; Henry NL; Hays RD; Kim S; Luu M; Diniz MA; Gresham G; Cecchini RS; Yothers G; Ganz PA; Rogatko A; Tighiouart M
    Cancer Prev Res (Phila); 2023 Nov; 16(11):631-639. PubMed ID: 37756580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events.
    Ip EH; Saldana S; Miller KD; Carlos RC; Gareen IF; Sparano JA; Graham N; Zhao F; Lee JW; O'Connell NS; Cella D; Peipert JD; Gray RJ; Wagner LI
    Cancer; 2021 Dec; 127(24):4546-4556. PubMed ID: 34726788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BioVis Explorer: A visual guide for biological data visualization techniques.
    Kerren A; Kucher K; Li YF; Schreiber F
    PLoS One; 2017; 12(11):e0187341. PubMed ID: 29091942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Safety Explorer Suite: Interactive Safety Monitoring for Clinical Trials.
    Wildfire J; Bailey R; Krouse RZ; Childress S; Sikora B; Bryant N; Rosanbalm S; Wilson E; Modell JG
    Ther Innov Regul Sci; 2018 Nov; 52(6):696-700. PubMed ID: 29714563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
    Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS; Forbes JF
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IPDmada: An R Shiny tool for analyzing and visualizing individual patient data meta-analyses of diagnostic test accuracy.
    Wang J; Keusters WR; Wen L; Leeflang MMG
    Res Synth Methods; 2021 Jan; 12(1):45-54. PubMed ID: 32808437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. InTool Explorer: An Interactive Exploratory Analysis Tool for Versatile Visualizations of Neuroscientific Data.
    Furcila D; García M; Toader C; Morales J; LaTorre A; Rodríguez Á; Pastor L; DeFelipe J; Alonso-Nanclares L
    Front Neuroanat; 2019; 13():28. PubMed ID: 30914926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an interactive web-based tool to conduct and interrogate meta-analysis of diagnostic test accuracy studies: MetaDTA.
    Freeman SC; Kerby CR; Patel A; Cooper NJ; Quinn T; Sutton AJ
    BMC Med Res Methodol; 2019 Apr; 19(1):81. PubMed ID: 30999861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
    J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GENAVi: a shiny web application for gene expression normalization, analysis and visualization.
    Reyes ALP; Silva TC; Coetzee SG; Plummer JT; Davis BD; Chen S; Hazelett DJ; Lawrenson K; Berman BP; Gayther SA; Jones MR
    BMC Genomics; 2019 Oct; 20(1):745. PubMed ID: 31619158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BioCyc Metabolic Network Explorer.
    Paley S; Karp PD
    BMC Bioinformatics; 2021 Apr; 22(1):208. PubMed ID: 33882841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.